Modified Vaccinia Ankara virus protein (MVA protein)

Modified Vaccinia Ankara (MVA) is a highly attenuated, replication-deficient orthopoxvirus that serves as a prominent viral vector platform for vaccines and immunotherapy (Volz & Sutter, 2017). MVA vector proteins refer to the collection of viral proteins encoded by the MVA genome, which was derived from the chorioallantois vaccinia virus Ankara (CVA) through extensive serial passage in chicken embryo fibroblasts, resulting in the loss of approximately 15% of the parental genome (Gilbert, 2013; PubMed: 23958243). These proteins are essential for the vector's ability to infect host cells and initiate the synthesis of both viral and recombinant proteins without producing infectious progeny in most mammalian cells. MVA proteins act as potent immunogens and natural adjuvants, stimulating innate immune pathways such as the cGAS-STING pathway and inducing robust CD8+ T-cell responses (NIH, 2023). In clinical practice, MVA-based products like Jynneos are used for the prevention of smallpox and mpox, while others are investigated as delivery vehicles for tumor-associated antigens in oncology (FDA, 2019). A primary challenge associated with MVA vector proteins is anti-vector immunity, where pre-existing or vaccine-induced antibodies against the MVA proteins can neutralize the vector upon repeated administration, potentially limiting its long-term efficacy.

Other names

Modified Vaccinia virus Ankara proteinsMVA-encoded proteinsMVA antigensMVA vector antigens

MVA vectors deliver genetic material into host cells where MVA proteins and transgenes are expressed, leading to the activation of innate immune sensors and the presentation of antigens to T and B cells (Volz & Sutter, 2017; PubMed: 28222772).